• 1. Chengdu Center of Disease Control and Prevention, Chengdu 610041, China;2. Chengdu University of Medical Science, Chengdu 610031, China;
SUN Ding, Email: 9822325@qq.com
Export PDF Favorites Scan Get Citation

Objective  To retrospectively analyze the morbidity, mortality, epidemiologic trends and distribution characteristic of top-three malignant tumors in Chengdu from 1990 to 2010, and to be aware of the incidence risk factors, and types and syn-position of main tumors, so as to provide evidence for the policy-making of tumor prevention and control.
Methods  ICD-10 coding method was used to categorize diseases and analyze the morbidity and mortality of malignant tumors seen in different ages, genders, areas and types, based on the surveillance data in Chengdu collected since 1990.
Results  The morbidity reports of top-three malignant tumors in Chengdu from 1999 to 2010 were lung cancer, liver cancer and colorectal cancer, the same as the mortality reports from 1999 to 2005, But the mortality of gastric cancer exceeded that of colorectal cancer and ranked as the third from 2005 to 2010. The mortality of top-three malignant tumors in male patients was higher than those in female patients. No difference was observed between urban and rural areas. The mortality of main malignant tumors rose along with the age growth.
Conclusion  Lung cancer, liver cancer and gastric cancer have become the main malignant tumors threatening Chengdu civilians, and their morbidity and mortality are rising yearly, which suggests that the prevention and control measures such as early diagnosis and treatment should be implemented aiming directly at those main tumors.

Citation: FENG Xixi,LIAO Jiang,HE Yan,LI Lei,SUN Ding. Epidemiological Characteristics of Top Three Malignant Tumors from 1990 to 2010 in Chengdu. Chinese Journal of Evidence-Based Medicine, 2012, 12(10): 1171-1174. doi: 10.7507/1672-2531.20120183 Copy

Copyright © the editorial department of Chinese Journal of Evidence-Based Medicine of West China Medical Publisher. All rights reserved

  • Previous Article

    Status Quo of Adaptive Design in Drug Development Trials and Its Prospective in Traditional Chinese Medicine Research
  • Next Article

    Comparisons among FLIC, SF-36 and QOL-LC in Measuring Quality of Life of Patients with Liver Cancer